Comparative Pharmacology
Head-to-head clinical analysis: PORTIA 21 versus QUASENSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PORTIA 21 versus QUASENSE.
PORTIA-21 vs QUASENSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
Quetiapine antagonist at dopamine D2 and serotonin 5-HT2A receptors; also affects histamine H1 and adrenergic α1 and α2 receptors.
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
100 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Terminal elimination half-life is 8–12 hours in healthy adults; prolonged to 20–30 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Primarily renal excretion (approximately 70% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for about 20% (including metabolites); 10% undergoes metabolic clearance.
Category C
Category C
Oral Contraceptive
Oral Contraceptive